Skye Bioscience (SKYE) Competitors $1.48 +0.03 (+1.72%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. TNXP, BIOA, SLS, ACRS, PLX, CHRS, DERM, GNFT, IVVD, and MDWDShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Tonix Pharmaceuticals (TNXP), BioAge Labs (BIOA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), Protalix BioTherapeutics (PLX), Coherus Oncology (CHRS), Journey Medical (DERM), GENFIT (GNFT), Invivyd (IVVD), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Its Competitors Tonix Pharmaceuticals BioAge Labs SELLAS Life Sciences Group Aclaris Therapeutics Protalix BioTherapeutics Coherus Oncology Journey Medical GENFIT Invivyd MediWound Tonix Pharmaceuticals (NASDAQ:TNXP) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Do analysts rate TNXP or SKYE? Tonix Pharmaceuticals presently has a consensus price target of $70.00, indicating a potential upside of 271.35%. Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 564.41%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Tonix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Is TNXP or SKYE more profitable? Skye Bioscience has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -828.22%. Tonix Pharmaceuticals' return on equity of -57.93% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-828.22% -57.93% -51.04% Skye Bioscience N/A -76.03%-69.20% Does the media prefer TNXP or SKYE? In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 5 articles in the media. Skye Bioscience's average media sentiment score of 0.49 beat Tonix Pharmaceuticals' score of -0.07 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TNXP or SKYE? Tonix Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Which has stronger earnings & valuation, TNXP or SKYE? Skye Bioscience has lower revenue, but higher earnings than Tonix Pharmaceuticals. Skye Bioscience is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M16.38-$130.04M-$39.47-0.48Skye BioscienceN/AN/A-$26.57M-$1.06-1.39 Do insiders and institutionals have more ownership in TNXP or SKYE? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummarySkye Bioscience beats Tonix Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.71M$3.42B$6.10B$10.49BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-1.3923.0484.6327.17Price / SalesN/A484.44608.51132.45Price / CashN/A46.9737.8662.13Price / Book0.6610.5112.356.62Net Income-$26.57M-$52.47M$3.33B$276.88M7 Day Performance-14.74%3.06%2.11%1.49%1 Month Performance-62.28%15.52%9.40%4.79%1 Year Performance-65.13%13.77%73.46%36.32% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience2.5295 of 5 stars$1.48+1.7%$9.80+564.4%-66.1%$45.71MN/A-1.3911TNXPTonix Pharmaceuticals2.8466 of 5 stars$23.00-5.0%$70.00+204.3%+18.3%$201.71M$10.09M-0.5850Short Interest ↑Gap DownBIOABioAge Labs0.2621 of 5 stars$5.60-0.5%N/AN/A$200.76MN/A0.00N/APositive NewsSLSSELLAS Life Sciences Group1.2952 of 5 stars$1.90+0.5%$7.00+268.4%+72.8%$200.06MN/A-5.9410Options VolumeACRSAclaris Therapeutics2.3908 of 5 stars$1.84-3.2%$8.71+373.6%+76.7%$199.33M$16.79M-1.34100News CoverageAnalyst ForecastAnalyst RevisionGap DownPLXProtalix BioTherapeutics1.6912 of 5 stars$2.50-3.8%$15.00+500.0%+120.2%$199.33M$61.95M-19.23200News CoverageHigh Trading VolumeCHRSCoherus Oncology4.189 of 5 stars$1.71+0.6%$4.51+163.9%+92.9%$198.75M$266.96M1.10330Positive NewsDERMJourney Medical1.9951 of 5 stars$7.55+3.6%$12.17+61.1%+17.8%$198.64M$56.40M-19.8790GNFTGENFIT2.1103 of 5 stars$3.96-1.7%$7.00+76.8%-33.8%$198.01M$41.52M0.00120Positive NewsAnalyst ForecastGap DownIVVDInvivyd3.9363 of 5 stars$1.63+14.8%$5.14+215.2%+77.5%$195.83M$25.38M-1.77100Analyst DowngradeMDWDMediWound1.9292 of 5 stars$17.54-1.0%$32.25+83.9%+8.3%$194.52M$20.22M-6.6480 Related Companies and Tools Related Companies TNXP Alternatives BIOA Alternatives SLS Alternatives ACRS Alternatives PLX Alternatives CHRS Alternatives DERM Alternatives GNFT Alternatives IVVD Alternatives MDWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
